Autoimmune Flyer

natures v autoimmune foundation

Donate to the Natures V Autoimmune Disease Foundation. Help Us change lives!


Distribute 100% of gifts made to NVADF in support of the clinical trials, research, treatment and clerical operations. NVADF distribution of your funding goes directly to our Autoimmune Disease clients for therapy and clinical trials. 

Mission Statement

NVADF is the only international nonprofit health agency dedicated to implementing a comprehensive focus to successfully treat autoimmune diseases. With over 100 serious chronic diseases, under the classification of autoimmune diseases, approximately 50 million Americans — or one in five people — suffer from autoimmune diseases. In some cases, Women are more likely than men to be affected; some estimates say 70% of those affected are women. Autoimmune Diseases is a major women’s health issue in America.

There are over 100 known autoimmune diseases. Most of these are known by their singular names, but the public is aware of their autoimmune nature. We must have organizations and foundations that are solution and result driven. NVADF is making the best results for treatment and therapy available to those who's health is adversely affected with immunological, autoimmune disorders. Successful treatment is needed to raise awareness of autoimmune diseases as a whole.

NVADF's research has found with autoimmune diseases as with acquired immune deficiency syndrome (AIDS), and other forms of cancers that there are successful treatments.

There is new knowledge, science and treatments surrounding immunology, autoimmunity successful therapy results. Now untold millions can be free from suffering and bringing those afflicted by these autoimmune diseases. Misdiagnosis, mis-prescribed and delayed diagnosis has resulted in damage health, life and well-being.


As with many organizations NVADF is also working in collaborative approach to provide research, funding, and early detection as it is essential to finding successful treatments, cures and preventative measures for all autoimmune diseases. 

Some of more well-known autoimmune diseases are lupus, type 1 diabetes, scleroderma, celiac, multiple sclerosis, Crohn’s disease, autoimmune hepatitis, rheumatoid arthritis, Graves’ disease, myasthenia gravis, myositis, antiphospholipid syndrome (APS), Sjogren’s syndrome, uveitis, vasculitis, relapsing polychondritis, and demyelinating neuropathies.

Donate to NVADF

Funding at NVADF is used to subsidize treatment costs to clients suffering with Autoimmune diseases. NVADF has a successful treat these maladies.


Your support and contributions will enable us to meet our goals and improve the conditions of any person with an AD . Your generous donation will fund our mission to provide those in need with our successful Cancer treatments.

Pay with PayPal or a debit/credit card

Natures V hvp Cancer immunotherapy foundation

NVADF Cancer Immunotherapy Foundation


 IMMUNOTHERAPY AND CANCER VACCINES Although there have been innumerable attempts over the years to use the immune system in the treatment of cancer, results have largely been disappointing, with success limited to treatments such as intravesical Bacillus Calmette-Guerin (BCG) for localised bladder cancer.30 By contrast, new immunotherapeutic approaches have begun to yield much more impressive results. Targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a key molecule that induces anergy and immune tolerance in antigen-specific T cells, has been a significant development in the treatment of stage IV melanoma.31 Ipilimumab, an inhibitor of CTLA-4 signalling, improves median OS when combined with a peptide vaccine (glycoprotein 100) from 6.4 to 10.0 months, when compared to treatment with vaccine alone.32 Other T cell coinhibitory receptor targeting agents have been developed and have shown promising results. An early phase trial studying an anti-programmed death 1 (PD-1) monoclonal antibody in NSCLC has shown encouraging response rates and an acceptable side effect profile.33 Cervical cancer is intimately associated with infection by the human papillomavirus (HPV), particularly subtypes HPV-16 or HPV-18. Cervical carcinomas contain HPV DNA integrated into the host cell genome, and two viral oncogenes, E6 and E7, are implicated in 90% of cases. HPV E6 induces accelerated proteasomal degradation of p53, while E7 binds and degrades the pRB retinoblastoma tumour suppressor protein.34 This affects the tumour signalling and growth control of cells. Various strains of the virus have been linked to cancer, in particular cervical, anal and head and neck cancers. The FUTURE (Females United to Unilaterally Reduce Endo/Ectocervical Disease) II trial randomised use of an HPV vaccine in 12 167 women between the ages of 15 and 26 years. In those not previously infected with the HPV-16 or HPV-18, there was a lower incidence of high-grade cervical intraepithelial neoplasia (CIN) and a reported vaccine efficacy against high-grade CIN of 17%.35 Since September 2008, there has been a national vaccination programme for girls aged 12–13 years. As cervical cancer is one of the leading causes of cancer-related death in developing countries, a worldwide vaccine programme would reduce cervical cancer risk on a global scale. For patients with metastatic prostate cancer, there is an option to use immunotherapy which has recently been approved by the FDA. The sipuleucel-T is a vaccine that uses autologous peripheral-blood mononuclear cells and activated antigenpresenting cells to stimulate an antitumour response. The IMPACT (Immunotherapy for Prostate Adenocarcinoma Treatment) study demonstrated a survival benefit of 4.1 months in sipuleucel-T group (25.8 months) compared to placebo (21.7 months).36 PROGRESS IN HORMONAL TREATMENT Androgens, oestrogens and progestins modulate the normal development of cells within the breast and prostate, while in the neoplastic cell these sex steroid hormones perpetuate growth. Although this does not correspond to a hallmark of cancer, hormones are required to perpetuate cancer cell growth, and the antihormonal agents were one of the first targeted agents in cancer drug development. These drugs spare the normal functions of the cell while depriving cancer cells of its important growth stimulus. Well known examples include oestrogen receptor modulators (eg, Tamoxifen) and aromatase inhibitors (eg, Letrozole), which have been beneficial in women with oestrogen receptor positive breast cancer. Hormonal therapy in breast cancer is relevant at all points in the treatment course, in the initial stages of management after surgery and in the metastatic setting. Due to its dependence of prostate cancer on testosterone to drive cell growth, treatment has relied heavily on hormonal agents that cause chemical castration. Luteinizing hormone releasing hormone (LHRH) analogues, such as goserelin, have been the mainstay of this for many years, however, it is common for resistance to emerge against. In such cases, termed castration-resistant prostate cancer, inhibition of a microsomal enzyme involved in androgen and oestrogen biosynthesis (Cytochrome P17) offers a new option for treatment. This inhibitor, Abiraterone, is well tolerated and has antitumour activity in combination with prednisolone in this population of heavily pretreated men.37 At 12.8 months follow-up, median OS was longer in the abiraterone–prednisone group than in the placebo–prednisone group (OS=14.8 vs 10.9 months).38